| . | HIV-1 RNA <20 Copies/mL,a No. (%) . | ||||||
|---|---|---|---|---|---|---|---|
| Treatment Groupb . | Baseline . | Day 3 . | Day 7 . | Day 14 . | Day 28 . | Wk 12 . | Wk 24 . |
| Blood plasma | |||||||
| DTG + 3TC (n = 16) | 0 | 0 | 0 | 5 (31) | 9 (56) | 14 (87) | 15 (94) |
| BIC/FTC/TAF (n = 8) | 0 | 0 | 1 (12) | 2 (25) | 6 (75) | 7 (87) | 7 (87) |
| P value | … | … | .333 | >.99 | .371 | >.99 | .602 |
| Seminal plasma | |||||||
| DTG + 3TC (n = 16) | 6 (37) | 6 (37) | 11 (69) | 14 (87) | 13 (81) | 15 (94) | 14 (87) |
| BIC/FTC/TAF (n = 8) | 3 (37) | 4 (50) | 6 (75) | 7 (87) | 7 (87) | 8 (100) | 8 (100) |
| P value | >.99 | .673 | .751 | >.99 | .699 | .470 | .296 |
| Rectal fluid | |||||||
| DTG + 3TC (n = 16) | 1 (6) | 6 (37) | 6 (37) | 10 (62) | 13 (81) | 15 (94) | 16 (100) |
| BIC/FTC/TAF (n = 8) | 0 | 1 (12) | 4 (50) | 4 (50) | 7 (87) | 8 (100) | 7 (87) |
| P value | >.99 | .352 | .673 | .673 | .699 | .470 | .149 |
| . | HIV-1 RNA <20 Copies/mL,a No. (%) . | ||||||
|---|---|---|---|---|---|---|---|
| Treatment Groupb . | Baseline . | Day 3 . | Day 7 . | Day 14 . | Day 28 . | Wk 12 . | Wk 24 . |
| Blood plasma | |||||||
| DTG + 3TC (n = 16) | 0 | 0 | 0 | 5 (31) | 9 (56) | 14 (87) | 15 (94) |
| BIC/FTC/TAF (n = 8) | 0 | 0 | 1 (12) | 2 (25) | 6 (75) | 7 (87) | 7 (87) |
| P value | … | … | .333 | >.99 | .371 | >.99 | .602 |
| Seminal plasma | |||||||
| DTG + 3TC (n = 16) | 6 (37) | 6 (37) | 11 (69) | 14 (87) | 13 (81) | 15 (94) | 14 (87) |
| BIC/FTC/TAF (n = 8) | 3 (37) | 4 (50) | 6 (75) | 7 (87) | 7 (87) | 8 (100) | 8 (100) |
| P value | >.99 | .673 | .751 | >.99 | .699 | .470 | .296 |
| Rectal fluid | |||||||
| DTG + 3TC (n = 16) | 1 (6) | 6 (37) | 6 (37) | 10 (62) | 13 (81) | 15 (94) | 16 (100) |
| BIC/FTC/TAF (n = 8) | 0 | 1 (12) | 4 (50) | 4 (50) | 7 (87) | 8 (100) | 7 (87) |
| P value | >.99 | .352 | .673 | .673 | .699 | .470 | .149 |
Abbreviations: 3TC, lamivudine; BIC, bictegravir; DTG, dolutegravir; FTC, emtricitabine; TAF, tenofovir alafenamide.
In the case of rectal fluid, <20 copies/swab.
P values are based on differences between groups by time within compartment type.
| . | HIV-1 RNA <20 Copies/mL,a No. (%) . | ||||||
|---|---|---|---|---|---|---|---|
| Treatment Groupb . | Baseline . | Day 3 . | Day 7 . | Day 14 . | Day 28 . | Wk 12 . | Wk 24 . |
| Blood plasma | |||||||
| DTG + 3TC (n = 16) | 0 | 0 | 0 | 5 (31) | 9 (56) | 14 (87) | 15 (94) |
| BIC/FTC/TAF (n = 8) | 0 | 0 | 1 (12) | 2 (25) | 6 (75) | 7 (87) | 7 (87) |
| P value | … | … | .333 | >.99 | .371 | >.99 | .602 |
| Seminal plasma | |||||||
| DTG + 3TC (n = 16) | 6 (37) | 6 (37) | 11 (69) | 14 (87) | 13 (81) | 15 (94) | 14 (87) |
| BIC/FTC/TAF (n = 8) | 3 (37) | 4 (50) | 6 (75) | 7 (87) | 7 (87) | 8 (100) | 8 (100) |
| P value | >.99 | .673 | .751 | >.99 | .699 | .470 | .296 |
| Rectal fluid | |||||||
| DTG + 3TC (n = 16) | 1 (6) | 6 (37) | 6 (37) | 10 (62) | 13 (81) | 15 (94) | 16 (100) |
| BIC/FTC/TAF (n = 8) | 0 | 1 (12) | 4 (50) | 4 (50) | 7 (87) | 8 (100) | 7 (87) |
| P value | >.99 | .352 | .673 | .673 | .699 | .470 | .149 |
| . | HIV-1 RNA <20 Copies/mL,a No. (%) . | ||||||
|---|---|---|---|---|---|---|---|
| Treatment Groupb . | Baseline . | Day 3 . | Day 7 . | Day 14 . | Day 28 . | Wk 12 . | Wk 24 . |
| Blood plasma | |||||||
| DTG + 3TC (n = 16) | 0 | 0 | 0 | 5 (31) | 9 (56) | 14 (87) | 15 (94) |
| BIC/FTC/TAF (n = 8) | 0 | 0 | 1 (12) | 2 (25) | 6 (75) | 7 (87) | 7 (87) |
| P value | … | … | .333 | >.99 | .371 | >.99 | .602 |
| Seminal plasma | |||||||
| DTG + 3TC (n = 16) | 6 (37) | 6 (37) | 11 (69) | 14 (87) | 13 (81) | 15 (94) | 14 (87) |
| BIC/FTC/TAF (n = 8) | 3 (37) | 4 (50) | 6 (75) | 7 (87) | 7 (87) | 8 (100) | 8 (100) |
| P value | >.99 | .673 | .751 | >.99 | .699 | .470 | .296 |
| Rectal fluid | |||||||
| DTG + 3TC (n = 16) | 1 (6) | 6 (37) | 6 (37) | 10 (62) | 13 (81) | 15 (94) | 16 (100) |
| BIC/FTC/TAF (n = 8) | 0 | 1 (12) | 4 (50) | 4 (50) | 7 (87) | 8 (100) | 7 (87) |
| P value | >.99 | .352 | .673 | .673 | .699 | .470 | .149 |
Abbreviations: 3TC, lamivudine; BIC, bictegravir; DTG, dolutegravir; FTC, emtricitabine; TAF, tenofovir alafenamide.
In the case of rectal fluid, <20 copies/swab.
P values are based on differences between groups by time within compartment type.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
